Fortis et al. have also demonstrated that high ratio between CD8+ and CD163+ cells evaluated in the tumor center, and the reverse low CD8+/CD163+ ratio in the tumor invasive margin, represent a valuable prognostic marker in breast cancer [16]. This evidence concerns the gene CD163 and breast cancer.